Should You Buy Tarsus Pharmaceuticals Inc (TARS) Stock on Friday?

Overall market sentiment has been down on Tarsus Pharmaceuticals Inc (TARS) stock lately. TARS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Tarsus Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TARS!

See Full TARS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With TARS Stock Today?

Tarsus Pharmaceuticals Inc (TARS) stock has risen 3.66% while the S&P 500 is down -0.43% as of 1:34 PM on Friday, Oct 27. TARS has gained $0.48 from the previous closing price of $13.16 on volume of 286,996 shares. Over the past year the S&P 500 is up 7.54% while TARS is down -21.25%. TARS lost -$3.40 per share in the over the last 12 months.

More About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Click Here to get the full Stock Report for Tarsus Pharmaceuticals Inc stock.